Gilead Sciences: New Harvoni Prescriptions Decelerate
June 19, 2015 at 13:18 PM EDT
RBC’s Michael Yee and John Chung have the latest prescription data for Gilead Sciences’ (GILD) hepatitis C treatment, and are predicting U.S. sale of $3.2 billion for the second quarter, just slightly beating consensus estimates. So why is Gilead’s share price inching lower today, falling 0.5% to a recent $120.55. China has rejected Gilead’s patent [...]